Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Rachel B. Keller et al.|Clinical Cancer Research|2023Cited by 46
Integrative genomic identification of therapeutic targets for pancreatic cancerJimmy A. Guo, Andrew J. Aguirre, Dennis Gong et al.|Cell Reports|2025Cited by 7
Abstract 2930: Intrinsic payload resistance governs responses to datopotamab deruxtecan, a TROP2 antibody drug conjugate, in pancreatic cancer model systemsPanot Sainamthip, Harshabad Singh, Kazuki Takahashi et al.|Cancer Research|2025Cited by 1
Supplementary Table S10 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Matthew Meyerson et al.|Unknown|2023Cited by 0
Supplementary Table S18 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, James M. Cleary et al.|Unknown|2023Cited by 0